The hold followed Intellia’s voluntary pause in response to a grade 4 liver event—a case of Hy’s Law—in the ATTR-CM trial. Shortly after the regulatory hold was implemented, Intellia disclosed that ...

TD Cowen analysts Mathew Blackman and Drew Ranieri have named their top three medtech picks under their evolving “Bones, Bots ...

Qilu Pharmaceutical has struck a deal to tap into Insilico Medicine’s artificial intellige | Qilu Pharmaceutical has struck a ...

What was once a barren field five years ago is now in a “virtuous cycle,” a transformation that Darsow felt firsthand as the ...

Ahead of its acquisition by cancer imaging company Kuva Labs, Lisata Therapeutics has regained the Chinese rights to its lead ...

United Therapeutics’ bioengineered external liver assist system developed to treat patients with acute forms of chronic liver ...

Spanish cancer biomarker medtech Reveal Genomics has boosted the roles of three of its founding members. | Spanish cancer biomarker medtech Reveal Genomics has boosted the roles of three of its ...

Heart attacks are often thought of as a plumbing issue, the result of a blockage preventing blood from flowing through one of ...

Roche’s dual GLP-1/GIP receptor agonist has been tied to 22.5% weight loss at 48 weeks, validating the company’s decision to move the asset into phase 3 studies this quarter.

Boehringer Ingelheim has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease (IBD) bispecific antibody. | Boehringer Ingelheim has penned a 1.

San Francisco-based startup Oath Surgical is partnering with tech giant Nvidia to enhance Oath’s artificial-intelligence-powered outpatient surgery center operating system. | Oath Surgical is ...

When Genenta Science listed on the Nasdaq at the tail-end of 2021, the Milan, Italy-based biotech was squarely focused on its pipeline of cell-based gene therapies. | Four years after listing on the ...